Selected Publications

Academic Article

Year Title Altmetric
2019 Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpuraBlood Advances.  3:4177-4186. 2019
2019 Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathyBlood.  134:1095-1105. 2019
2019 Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiolsJournal of Thrombosis and Haemostasis.  17:596-606. 2019
2019 Significantly prolonged PT and APTT could indicate a wide spectrum of clinical manifestations in three patients with plasma cell disordersClinical and Laboratory Haematology.  41:e23-e26. 2019
2019 Relative Deficiency of Plasma A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeats 13 Activity and Elevation of Human Neutrophil Peptides in Patients with Traumatic Brain InjuryJournal of Neurotrauma.  36:222-229. 2019
2019 Apolipoprotein B100/Low-Density Lipoprotein Regulates Proteolysis and Functions of von Willebrand Factor under Arterial ShearThrombosis and Haemostasis.  119:1933-1946. 2019
2019 Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpuraHaematologica.  104:166-175. 2019
2018 Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric TraumaThrombosis and Haemostasis.  118:676-687. 2018
2018 Transfusion of platelets loaded with recombinant ADAMTS13 (A disintegrin and metalloprotease with thrombospondin type 1 repeats-13) is efficacious for inhibiting arterial thrombosis associated with thrombotic thrombocytopenic purpuraArteriosclerosis, Thrombosis, and Vascular Biology.  38:2731-2743. 2018
2017 Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity: commentJournal of Thrombosis and Haemostasis.  15:586-589. 2017
2017 Increased Plasma Levels of Human Neutrophil Peptides and Complement Activation Markers in Patients With Acquired Thrombotic Thrombocytopenic Purpura.American Journal of Clinical Pathology.  147:S154. 2017
2017 Plasma ADAMTS13 activity and von Willebrand factor antigen and activity in patients with subarachnoid haemorrhageThrombosis and Haemostasis.  117:691-699. 2017
2016 Acquired autoimmune thrombotic thrombocytopenic purpura in a case of severe haemophilia AHaemophilia.  22:e565-e567. 2016
2016 Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpuraHaematologica.  101:1319-1326. 2016
2015 ADAMTS13 and von Willebrand factor interactionsCurrent opinion in hematology.  22:452-459. 2015
2014 Efficient production of dual recombinant adeno-associated viral vectors for factor VIII deliveryHuman Gene Therapy Methods.  25:261-268. 2014
2012 Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloproteaseJournal of Biological Chemistry.  287:32459-32466. 2012
2010 Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stressJournal of Biological Chemistry.  285:28596-28603. 2010
2010 Mutation of the protein kinase A phosphorylation site influences the anti-proliferative activity of mitofusin 2Atherosclerosis.  211:216-223. 2010
2009 Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage siteBlood.  114:1666-1674. 2009
2009 Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapyBlood.  113:2172-2180. 2009
2009 Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genesMolecular Therapy.  17:34-41. 2009
2008 Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cellsJournal of Thrombosis and Haemostasis.  6:1233-1235. 2008
2008 Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13Proceedings of the National Academy of Sciences.  105:7416-7421. 2008
2006 Adenovirus-mediated Mfn2 gene induces the apoptosis of vascular smooth muscle cells after ballon injury of rat carotid arteryChinese Journal of Emergency Medicine.  15:506-509. 2006
2005 Monitoring CML28 mRNA levels in patients before and after HSCT by real-time quantitative RT-PCRZhongguo Shi Yan Xue Ye Xue Za Zhi // Zhongguo Bing Li Sheng Li Xue Hui == Journal of Experimental Hematology // Chinese Association of Pathophysiology.  13:843-847. 2005
2004 Liposome-mediated functional expression of multiple drug resistance gene in human bone marrow CD34+ cellsJournal- Tongji Medical University.  24. 2004
2004 Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937Journal- Tongji Medical University.  24:45-47. 2004
2004 Inhibition of NF-kappaB by mutant IkappaBalpha enhances TNF-alpha-induced apoptosis in HL-60 cells by controlling bcl-xL expression.Chinese Medical Journal.  117:972-977. 2004
2004 Inhibition of NF-κB by mutant IκBα enhances TNF-α -induced apoptosis in HL-60 cells by controlling bcl-XL expressionChinese Medical Journal.  117:972-977. 2004
2002 Regulative function of telomerase and extracelluar regulated protein kinases to leukemic cell apoptosisJournal- Tongji Medical University.  22. 2002
2002 Regulative function of extracelluar regulated protein kinases and telomerase in apoptosis of hepatocarcinomatous cell SMMC-7721Zhonghua Gan Zang Bing Za Zhi ==.  10:287-288. 2002
2001 [Antisense Oligodeoxynucleotide Directed to NF-kappaB-RelA Down-Regulates bcl-x(L) mRNA in Drug-Resistant Leukemia Cell Line HL-60/E6]Zhongguo Shi Yan Xue Ye Xue Za Zhi // Zhongguo Bing Li Sheng Li Xue Hui == Journal of Experimental Hematology // Chinese Association of Pathophysiology.  9:294-297. 2001
2001 Effect of antisense oligodeoxynucleotide directed to NF-κB-RelA on bcl-x L mRNA in extended drug resistance leukemia cell line HL-60/E6Journal- Tongji Medical University.  21:32-34. 2001

Full Name

  • Wenjing Cao